Phillip Febbo Sells 13,110 Shares of Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. (NASDAQ:VCYT) insider Phillip Febbo sold 13,110 shares of Veracyte stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $43.05, for a total transaction of $564,385.50. Following the completion of the transaction, the insider owned 133,048 shares of the company’s stock, valued at $5,727,716.40. This trade represents a 8.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Veracyte Price Performance

Shares of VCYT opened at $42.53 on Friday. The company has a market capitalization of $3.42 billion, a P/E ratio of 30.16 and a beta of 1.93. Veracyte, Inc. has a one year low of $29.45 and a one year high of $60.91. The business’s 50 day simple moving average is $50.64 and its 200-day simple moving average is $43.12.

Veracyte (NASDAQ:VCYT) last released its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Veracyte had a return on equity of 9.26% and a net margin of 20.37%.The firm had revenue of $150.32 million during the quarter, compared to analysts’ expectations of $144.59 million. During the same period last year, the firm posted $0.44 EPS. The business’s revenue was up 15.5% on a year-over-year basis. On average, sell-side analysts anticipate that Veracyte, Inc. will post 1.32 EPS for the current fiscal year.

Key Headlines Impacting Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Institutional ownership trends remain supportive. Bank of America, Royal Bank of Canada and William Blair increased their positions, while Summit Creek Advisors and Deutsche Bank initiated new stakes. Analysts maintain a “Moderate Buy” consensus with an average price target of $54.33, above recent trading levels. Veracyte insider trading and institutional ownership report
• Neutral Sentiment: Veracyte’s most recent reported quarter showed earnings of $0.54 per share versus the $0.41 consensus estimate, while revenue rose 15.5% year over year to $150.32 million. These results provide a fundamental backdrop of continued growth, although they are not new developments in the latest disclosures.
• Negative Sentiment: EVP Annie McGuire sold 3,254 shares for approximately $140,215, CFO Rebecca Chambers sold 3,652 shares for about $157,401, and insider Phillip Febbo sold 13,110 shares valued at roughly $564,386. Each transaction was executed through a 10b5-1 plan to cover taxes, and the sellers retained substantial positions, limiting the signal that management is broadly abandoning the stock. Veracyte executive stock sale filing
• Negative Sentiment: Director Muna Bhanji separately sold 1,864 shares for approximately $80,096, reducing her position by 4.18%. The sale was also pre-arranged, but the cluster of insider transactions may reinforce short-term caution among investors. Muna Bhanji Veracyte stock sale

Hedge Funds Weigh In On Veracyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VCYT. Bank of America Corp DE grew its holdings in Veracyte by 14.7% during the first quarter. Bank of America Corp DE now owns 1,448,897 shares of the biotechnology company’s stock valued at $46,669,000 after purchasing an additional 185,929 shares during the period. Summit Creek Advisors LLC acquired a new stake in Veracyte in the second quarter worth $6,986,000. William Blair Investment Management LLC boosted its position in shares of Veracyte by 16.6% during the fourth quarter. William Blair Investment Management LLC now owns 790,425 shares of the biotechnology company’s stock worth $33,277,000 after purchasing an additional 112,516 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Veracyte by 66.4% in the 1st quarter. Royal Bank of Canada now owns 573,096 shares of the biotechnology company’s stock valued at $18,459,000 after buying an additional 228,720 shares during the period. Finally, Rice Hall James & Associates LLC bought a new stake in shares of Veracyte in the 2nd quarter valued at $5,614,000.

Analyst Upgrades and Downgrades

VCYT has been the subject of several research reports. Wall Street Zen upgraded shares of Veracyte from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Zacks Research raised shares of Veracyte from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group dropped their price objective on shares of Veracyte from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Piper Sandler dropped their price objective on Veracyte from $66.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Finally, Stephens reduced their target price on shares of Veracyte from $68.00 to $55.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.33.

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.